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within and between the MTM members and controls were measured (difference-
in-differences (DID) analysis). Results: 2382 patients (MTM group: n= 201, mean 
age= 75,44%male; control group: n= 2181,mean age= 74,48%male) in the diabetes 
cohort and 9751 patients (MTM group: n= 563, mean age= 76,39% male; control 
group: n= 9188, mean age= 75,40% male) in the hypertension cohort were included. 
For patients in diabetes cohort, the MTM group had pre-post increase in PDC by 
5.19% (P= 0.05), while the control group had decrease of 2.82% (P< 0.01) (DID= 8.03%; 
P= 0.003). For patients in hypertension cohort, the MTM group had pre-post 
increase in PDC by 17.33% (P< 0.01), while the control group had increase of 9.64% 
(P< 0.01) (DID= 7.67%; P< 0.01). The PDC finding was confirmed with regression 
analyses with propensity score adjustment showing the MTM groups had a sig-
nificant increase in pre-post PDC for hypertension, as compared with the control 
group, while controlling for baseline characteristics (P= 0.01). ConClusions: This 
study found that the pharmacist-managed MTM program significantly increased 
medication adherence in Medicare MAPD patients with hypertension, as compared 
with a control group.
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objeCtives: Oral Antidiabetics (OAD) have been shown to reduce the risk of mor-
tality, particularly among metformin users, which had risk reductions of 36% for 
cardiovascular-related death and 33-40% for all-cause mortality. However, very few 
studies have assessed adherence to OAD and all-cause mortality. A population-based 
nested case-control study design was used to investigate the relationship between 
adherence to OAD and all-cause mortality among incident users of OAD. Methods: 
Incident OAD users were identified using healthcare databases of residents covered by 
the public drug insurance plan of the Province of Quebec, Canada. Patients initiated 
OAD therapy between 2000 and 2009 and were aged 45-85 years at cohort entry. A 
nested case-control design was conducted to study mortality occurrence. Each case 
was matched to 10 controls by gender, age and duration of follow-up. The adherence 
to OAD was measured by calculating the medication possession ratio. Conditional 
logistic regression models were used to estimate the association between adherence 
to OAD and all-cause mortality adjusting for various potential confounders. Results: 
The cohort included 63,859 incident OAD users at entry: mean age was 68 years old, 
45% were male, 37% had coronary artery disease, 82% had hypertension, and 62% 
dyslipidemia. Most patients initiated their OAD treatment with biguanides (78%) 
and sulfonylureas (12%). The average follow up time was 48 months. Among those 
deemed adherent, the risk of mortality was decreased compared to nonadherent (Rate 
ratio: 0.67 [95%CI 0.64-0.70]). The likelyhood for mortality was higher for patients with 
heart failure (1.56 [1.49-1.65]), ≥ 2 cardiovascular diseases (1.45 [1.39-1.52]), amputa-
tions (2.03 [1.42-2.91]), chronic viral infections (1.73 [1.44-2.07]), corticosteroid use 
(1.69 [1.56-1.89]), and ≥ 1 hospital admissions (1.73 [1.65-1.80]). Conversely, mortality 
was least likely for patients with dyslipidemia (0.76 [0.73-0.79]), and hypertension 
(0.88 [0.83-0.94]). ConClusions: Adherence to OAD seems to be associated with a 
risk reduction of mortality. Further research is needed to confirm this risk. Residual 
confounding may remain a potential issue.
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objeCtives: To assess basal insulin persistence, associated factors, and economic 
outcomes for insulin-naïve people with Type 2 diabetes mellitus (T2DM) in Japan 
using health insurance claims data. Methods: People aged ≥ 18 years diagnosed 
with T2DM with their first claim for basal insulin between 5/2006-4/2013 (index 
date), no insulin use before index date, and continuous insurance coverage for 6 
months before (baseline) and 12 months after index date were selected from the 
Japan Medical Center Database. Based on whether there were ≥ 30 day-gaps in basal 
insulin use, patients were classified as continuers (no gap), interrupters (≥ 1 prescrip-
tion after gap), and discontinuers (no prescription after gap). Multinomial logistic 
regression model was used to identify factors associated with persistence. Annual 
healthcare resource use and costs were compared separately between continuers 
and interrupters, and continuers and discontinuers using propensity score-based 
inverse probability weighting to adjust for baseline differences. Results: Of the 
827 people included in the sample (mean age: 50 years, ~71% male), 36% continued, 
42% interrupted, and 22% discontinued basal insulin therapy in the year after initia-
tion. Inpatient visits and using fewer classes of non-insulin antidiabetic medica-
tions during baseline were associated with higher likelihoods of interrupting or 
discontinuing insulin therapy. Relative to interrupters and discontinuers, continu-
ers had lower hospitalization rates (continuers:12.7%, interrupters:25.4% [p< 0.001], 
discontinuers:28.4% [p< 0.001]) and lower inpatient costs (continuers:JPY132,013, 
interrupters:JPY225,745 [p= 0.054], discontinuers:JPY320,582 [p= 0.036]), but 
higher pharmacy costs (continuers:JPY158,403, interrupters:JPY134,301 [p= 0.039], 
discontinuers:JPY121,593 [p= 0.002]) in the year after insulin initiation. The total 
healthcare costs were similar for the three cohorts. ConClusions: Substantial 
proportions of people with T2DM initiating basal insulin in Japan interrupt or dis-
continue treatment within the year after initiation, and they have higher rates and 
costs of hospitalizations than continuers. Further research is needed to understand 
reasons behind basal insulin persistence and the implications thereof, to help clini-
cians manage T2DM more effectively.
ated over a 60-year horizon, discounted at 3.5% annually. Results: Mean life 
expectancy of 61.4 years and 22.7 (14.1) undiscounted (discounted) QALYs were 
predicted. Maintaining a 1% reduction in HbA1c was associated with an estimated 
gain of 0.54 QALYs per patient. A 3kg weight loss and 30% reduction in frequency 
of symptomatic hypoglycaemic episodes produced a combined QALY gain of 0.38 
(77% attributable to weight loss), whereas the reverse gave a QALY decrement of 
0.87 (93% attributable to weight gain). ConClusions: The beneficial effects of 
improved glycaemic control on QALYs, achieved through the avoidance of diabetes 
related complications, may be offset by characteristic treatment-specific adverse 
effects, such as weight gain and frequency of hypoglycaemia. The comparative 
weight and hypoglycaemic profiles of available therapies are therefore key to both 
their cost-effectiveness and effectiveness in clinical practice.
PDB77
the role of selectIve InhIBItors of soDIum-glucose co-conveyor 
tyPe 2 In reDucIng of vascular aftereffects
Meshkov DO, Khabriev  RU, Bezmelnitsyna LY, Berseneva EA, Cherkasov SN
National Research Institution for Public Health, Moscow, Russia
objeCtives: Diabetes Mellitus II (DM type II) is characterized by high prevalence 
and severe vascular complications. They are the main cause of disability and death 
in DM patients and lead to grave social and economic consequences. The objective of 
the present study was to assess the impact of selective inhibitors of sodium-glucose 
co-conveyor type 2 on frequency of complications and the costs per QALY compar-
ing with inhibitors dipeptidyl peptidase-4 type. Methods: Modeling using Global 
«Cardiff diabetes model» in time horizon of 25 years. Strategy I: Line I - selective inhibi-
tors of sodium-glucose co-conveyor type 2 (for example, dapagliflozin), Line II - Line I 
+ metformin; Line III: insulin. Strategy II: Line I - inhibitors dipeptidyl peptidase-4 type 
(for example, sitagliptin); Line II - Line I + metformin; Line III: insulin. The direct medi-
cal costs of medicines, out -patients care and fatal complications were evaluated and 
cost utility analysis (CUA) were held. Results: The direct medical costs for Strategy I 
for 1000 patients during 25 years were 5 309 305 USD: for Strategy II - 5 316 676 USD (7 
371 USD higher). The strategy I helps to prevent the 11 fatal complications among 1000 
DM type II patients. Reducing the frequency of complications provide saving 22 523 
USD for cohort during 25 years. Costs per QALY for Strategy I were on 26 UDS less than 
for Strategy II. The results of CUA were proved by sensitivity analysis. ConClusions: 
Present study has shown that selective inhibitors of sodium-glucose co-conveyor 
type 2 is more cost-effective as a first line therapy thanks to reducing the frequency 
of fatal vascular complications and the costs per QALY.
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objeCtives: Hypoglycaemic episodes are a common side-effect of anti-diabetes 
therapy. The impact and associated costs of severe episodes (i.e. episodes that 
the patient is unable to treat themselves) has been extensively reported. There 
is less information about non-severe hypoglycaemic episodes (NSHE). The objec-
tive was to investigate the costs and resource use associated with NSHEs across 
a number of different countries in Europe. Methods: The ‘Hypoglycaemia in 
Insulin Treated patients’ (HIT) study has recently been completed and reported 
for 11 countries across Europe, reporting data from 6,502 patients. Along with data 
on the frequency and impact of NSHE, the study also collected data on resource 
use associated with NSHEs. Data from ten of the countries were utilized, along 
with published, country specific, cost data to calculate an average NSHE cost in 
each country. Resource use differed for different types of diabetes, costs for Type 
1 diabetes (T1D), and Type 2 diabetes (T2D) are reported separately. Results: 
NSHEs required additional blood glucose tests (3.3-8.2). The numbers differed 
depending on country, type of diabetes (T1D:3.3-7.7; T2D: 1.3-8.2) and whether 
the event was diurnal or nocturnal (min: 1.3-3.7; max: 6.2-8.2). Additionally a 
number (T1D: 0% - 16%; T2D: 3% - 23%), highest in Spain and Germany, of NSHEs 
resulted in contact with healthcare professionals. The average cost (per NSHE) to 
the healthcare system was € 4.34 (T1D - range € 2.10 – € 6.80) ; and € 6.20 (T2D - range 
€ 2.10 – € 11.20). ConClusions: NSHEs pose a substantial burden to healthcare 
systems, and society. While individual episodes incur only a small cost, episodes 
are common, and the frequency of NSHEs means that costs for a country can 
be considerable. In addition to this – the patients will often also bear the cost of 
rescue treatments such as a snack or glucose tablets.
DIaBetes/enDocrIne DIsorDers – Patient-reported outcomes & Patient 
Preference studies
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objeCtives: In 2014, the University of Florida College of Pharmacy’s Medication 
Therapy Management (MTM) Communication and Care Center provided an opt-in 
telephone MTM program to eligible Medicare beneficiaries, who were enrolled in 
AvMed Health Plan, a regional Part D plan in Florida. The objective of this study 
was to determine the impact of pharmacist-provided telephone MTM on medica-
tion adherence in elderly patients with hypertension and diabetes. Methods: 
A retrospective analysis using the AvMed Health Plans (Jan 2013-2014 Dec) was 
conducted for Medicare Advantage Prescription Drug (MAPD) plan beneficiaries 
who received at least two oral anti-diabetics (Diabetes Cohort) and oral anti-hyper-
tensives (Hypertension Cohort), respectively. Adherence, defined by proportion 
of days covered (PDC), was measured using incurred drug claims 6-month before 
and after the MTM program was implemented. Pre-post differences in the PDC 
